Amplyx Pharmaceuticals Overview

  • Founded
  • 2006

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 26

Employees
  • Latest Deal Type
  • M&A

Amplyx Pharmaceuticals General Information

Description

Developer of antifungal agents intended to treat invasive fungal infections. The company's agents use both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from the hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus, and rare molds.

Contact Information

Website
www.amplyx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Primary Office
  • 12730 High Bluff Drive
  • Suite 160
  • San Diego, CA 92130
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amplyx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 28-Apr-2021 00000 Completed Generating Revenue
5. Secondary Transaction - Private 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 09-Jan-2020 000.00 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series B) 27-Jun-2017 000.00 000.00 0000 Completed Generating Revenue
2. Grant 01-Jan-2017 $11.3M $2.3M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2011 $2.3M $2.3M 000 Completed Generating Revenue
To view Amplyx Pharmaceuticals’s complete valuation and funding history, request access »

Amplyx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 8,243,027 $0.001000 8% $0.27 $0.27 1x $0.27 2.04%
To view Amplyx Pharmaceuticals’s complete cap table history, request access »

Amplyx Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antifungal agents intended to treat invasive fungal infections. The company's agents use both intravenous a
Drug Discovery
San Diego, CA
26 As of 2021
00000
000000&0 00000

000000

scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000 000000000
San Diego, CA
000 As of 0000
00000
0000000 0000 00000

000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000 000000000
Manchester, United Kingdom
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amplyx Pharmaceuticals Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biosplice Therapeutics Private Equity-Backed San Diego, CA 000 00000 0000000 0000 00000
000 Venture Capital-Backed Manchester, United Kingdom 00 00000 0000000000 0 00000
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
000000 00000000000 Private Equity-Backed Copenhagen, Denmark 0000 000000000000
0000000 Venture Capital-Backed Wuppertal, Germany 00 000.00 0000000000 000.00
You’re viewing 5 of 28 competitors. Get the full list »

Amplyx Pharmaceuticals Patents

Amplyx Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021536446-A Compounds and methods for treating fungal infections Pending 31-Aug-2018 0000000000
EP-3843769-A1 Compounds and methods for treating fungal infections Pending 31-Aug-2018 0000000000
CA-3110860-A1 Compounds and methods for treating fungal infections Pending 31-Aug-2018 0000000000
AU-2019328599-A1 Compounds and methods for treating fungal infections Pending 31-Aug-2018 0000000000
US-20210290644-A1 Compounds and methods for treating fungal infections Pending 31-Aug-2018 A61K31/444
To view Amplyx Pharmaceuticals’s complete patent history, request access »

Amplyx Pharmaceuticals Board Members (13)

Name Representing Role Since
Edward Mathers Self Board Member 000 0000
You’re viewing 1 of 13 board members. Get the full list »

Amplyx Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amplyx Pharmaceuticals Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3x5 Partners Venture Capital Minority 000 0000 000000 0
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Ariel Savannah Angel Partners Angel Group Minority 000 0000 000000 0
Arix Bioscience Venture Capital Minority 000 0000 000000 0
BioMed Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 22 investors. Get the full list »